2022
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study
Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, McCoy RG. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. The BMJ 2022, 379: e070717. PMID: 36191949, PMCID: PMC9527635, DOI: 10.1136/bmj-2022-070717.Peer-Reviewed Original ResearchConceptsSecondary outcomesMetformin monotherapyTreatment groupsRetrospective comparative effectiveness studyCox proportional hazards regressionPropensity scoreIncident microvascular complicationsNationwide claims databaseProportional hazards regressionType 2 diabetesComparative effectiveness studiesMacrovascular complicationsMicrovascular complicationsProspective trialAdverse eventsGlycemic controlHospital admissionInsulin glarginePrimary outcomeMedian timeHazards regressionClaims databaseObservational studyInverse propensity scoreEligibility criteria
2021
Long-Term Complications in Youth-Onset Type 2 Diabetes
Bjornstad P, Drews K, Caprio S, Gubitosi-Klug R, Nathan D, Tesfaldet B, Tryggestad J, White N, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. New England Journal Of Medicine 2021, 385: 416-426. PMID: 34320286, PMCID: PMC8697255, DOI: 10.1056/nejmoa2100165.Peer-Reviewed Original ResearchConceptsType 2 diabetesDiabetic kidney diseaseNerve diseaseKidney diseaseRetinal diseasesYouth-Onset Type 2Minority raceDevelopment of complicationsIncidence of dyslipidemiaRisk of complicationsMulticenter clinical trialDiagnosis of diabetesMicrovascular complicationsAdverse eventsCumulative incidenceTerm complicationsGlycemic controlRelated complicationsObservational followMean ageRisk factorsClinical trialsComplicationsDyslipidemiaHypertensionAssociations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes.
Gubitosi-Klug R, Gao X, Pop-Busui R, de Boer IH, White N, Aiello LP, Miller R, Palmer J, Tamborlane W, Wallia A, Kosiborod M, Lachin JM, Bebu I. Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. Diabetes Care 2021, 44: 1499-1505. PMID: 33980605, PMCID: PMC8323173, DOI: 10.2337/dc20-3104.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAlbumin excretion rateNonfatal myocardial infarctionSubsequent cardiovascular diseaseCardiovascular diseaseMicrovascular complicationsMyocardial infarctionMicrovascular diseaseSubsequent riskDCCT/EDIC cohortTraditional CVD risk factorsUrinary albumin excretion rateAdvanced microvascular diseaseSubclinical myocardial infarctionAdverse cardiovascular eventsCoronary artery revascularizationCVD risk factorsGlomerular filtration rateSignificant macular edemaType 1 diabetesProportional hazards modelRetinal fundus photographyArtery revascularizationComplications StudyNonfatal stroke
2020
Diabetic Retinopathy and Risk of Stroke
Wong KH, Hu K, Peterson C, Sheibani N, Tsivgoulis G, Majersik JJ, de Havenon AH. Diabetic Retinopathy and Risk of Stroke. Stroke 2020, 51: 3733-3736. PMID: 33019896, PMCID: PMC7686117, DOI: 10.1161/strokeaha.120.030350.Peer-Reviewed Original ResearchConceptsBlood pressure interventionsRisk of strokeDiabetic retinopathyRandomization armIncident strokePrimary outcomePressure interventionPresence of DRCox proportional hazards modelACCORD Eye StudyRapid vision lossSubsequent stroke eventsCommon microvascular complicationCox regression modelProportional hazards modelMacrovascular complicationsMicrovascular complicationsHazard ratioEye StudyMicrovascular pathologyStroke eventsStudy baselineSerum glucoseVision lossHazards modelCirculating markers of angiogenesis and endotheliopathy in COVID‐19
Pine AB, Meizlish ML, Goshua G, Chang C, Zhang H, Bishai J, Bahel P, Patel A, Gbyli R, Kwan JM, Won CH, Price C, Dela Cruz CS, Halene S, van Dijk D, Hwa J, Lee AI, Chun HJ. Circulating markers of angiogenesis and endotheliopathy in COVID‐19. Pulmonary Circulation 2020, 10: 1-4. PMID: 33282193, PMCID: PMC7691906, DOI: 10.1177/2045894020966547.Peer-Reviewed Original ResearchCOVID-19 infectionMarkers of angiogenesisEndothelial injuryDisease severityCOVID-19-associated coagulopathyCritical COVID-19 infectionCOVID-19 pathogenesisCOVID-19COVID-19 diseaseEndothelial cell functionHospital mortalityMicrovascular complicationsCritical illnessElevated markersHospitalized patientsPatient populationFuture therapiesPlasma profilingSurvival analysisPatientsInfectionCell functionPotential targetInjuryMarkersEndotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patientsUse of venous couplers in microsurgical lower extremity reconstruction: A systematic review and meta‐analysis
Haug V, Panayi A, Kadakia N, Abdulrazzak O, Endo Y, Udeh K, Kollar B, Hundeshagen G, Pomahac B, Kneser U, Hirche C. Use of venous couplers in microsurgical lower extremity reconstruction: A systematic review and meta‐analysis. Microsurgery 2020, 41: 50-60. PMID: 32227603, DOI: 10.1002/micr.30581.Peer-Reviewed Original ResearchConceptsLower limb reconstructionHand-Sewn AnastomosisSystematic reviewLimb reconstructionVenous couplerMicrosurgical lower extremity reconstructionMore surgical complicationsAdditional prospective studiesMeta-Analyses (PRISMA) guidelinesLower extremity reconstructionFree tissue transferFull-text reviewQuality of reportingWeb of ScienceMicrovascular complicationsSurgical complicationsArterial compromiseCochrane CollaborationProspective studyCase reportVenous anastomosisClinical trialsLower extremitiesSurgical techniqueInclusion criteria
2018
Diabetes medications and cardiovascular disease
Lupsa BC, Inzucchi SE. Diabetes medications and cardiovascular disease. Current Opinion In Endocrinology Diabetes And Obesity 2018, 25: 87-93. PMID: 29369916, DOI: 10.1097/med.0000000000000400.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsType 2 diabetes mellitus patientsPeptide-1 receptor agonistsGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetes mellitus patientsType 2 diabetesCause of mortalityCardiovascular complicationsCardiovascular outcomesDiabetes medicationsMicrovascular complicationsCardiovascular effectsMellitus patientsReceptor agonistDrug categoriesIntensive controlDiseaseComplicationsMedicationsClear benefitRecent studiesSignificant improvement
2017
Effects of diabetic retinopathy on the barrier functions of the retinal pigment epithelium
Xia T, Rizzolo LJ. Effects of diabetic retinopathy on the barrier functions of the retinal pigment epithelium. Vision Research 2017, 139: 72-81. PMID: 28347688, DOI: 10.1016/j.visres.2017.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBlood-retinal barrierRetinal pigment epitheliumOuter blood-retinal barrierRPE barrier functionDiabetic retinopathyBarrier functionPigment epitheliumInner blood-retinal barrierEffect of diabetesRetinal endothelial cellsMicrovascular complicationsDiabetes mellitusNeurosensory retinaRetinal healthParacellular spaceRetinopathyMetabolic processingEndothelial cellsEarly effectsDiabetesActive transportTight junctionsCulture modelEpitheliumTransepithelial movement
2016
Anxiety among patients with diabetes mellitus evaluated using generalized anxiety disorder 7-item scale
Thour A, Nagra R, Gosal A, Sehrawat T, Das S, Gupta Y. Anxiety among patients with diabetes mellitus evaluated using generalized anxiety disorder 7-item scale. Journal Of Social Health And Diabetes 2016, 04: 133-136. DOI: 10.4103/2321-0656.187988.Peer-Reviewed Original ResearchTertiary care hospitalPrevalence of anxietyDiabetes mellitusCare hospitalType 2 diabetes mellitusDuration of diabetesType 2 diabetesYears of ageAssociation of anxietyMicrovascular complicationsEndocrine clinicEndocrinology clinicPoor outcomePlasma glucoseHigh prevalencePatientsComorbid anxietySevere anxietyDiabetesMellitusMild anxietySociodemographic profileAnxiety disordersModerate anxietyGeneralized anxietyIRS proteins and diabetic complications
Lavin D, White M, Brazil D. IRS proteins and diabetic complications. Diabetologia 2016, 59: 2280-2291. PMID: 27514532, PMCID: PMC5506098, DOI: 10.1007/s00125-016-4072-7.Peer-Reviewed Original ResearchConceptsIRS proteinsType 2 diabetesDiabetic complicationsMitogen-activated protein kinaseElicit cellular responsesCoronary artery diseaseElevated blood glucoseComplications of diabetesProtein kinaseDownstream effectorsAdaptor moleculeInsulin signalingCellular responsesNumber of organsInsulin receptorMacrovascular complicationsMicrovascular complicationsArtery diseasePatient morbidityBlood glucoseProteinMale micePatient outcomesCell proliferationComplications
2015
Beyond HbA1c: Environmental Risk Factors for Diabetic Retinopathy
Nwanyanwu KH, Newman-Casey PA, Gardner TW, Lim JI. Beyond HbA1c: Environmental Risk Factors for Diabetic Retinopathy. Journal Of Clinical & Experimental Ophthalmology 2015, 06: 405. PMID: 26973797, PMCID: PMC4785841, DOI: 10.4172/2155-9570.1000405.Peer-Reviewed Original ResearchEnvironmental risk factorsDiabetic retinopathyRisk factorsDuration of diseaseDiabetic eye diseasePrevalence of diabetesCause of blindnessCost-effective interventionWorking-aged peopleMicrovascular complicationsEye diseasePopulation-level challengesRetinopathyDiseaseDiabetesBlindnessComplicationsFactorsPrevalenceCardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes
Lipes M, Galderisi A. Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes. Current Diabetes Reports 2015, 15: 30. PMID: 25821130, PMCID: PMC4376963, DOI: 10.1007/s11892-015-0598-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular diseaseHeart diseaseChronic myocardial inflammationPoor CVD outcomesUnderstanding of CVDType 1 diabetesCardiac autoimmunityMicrovascular complicationsCVD outcomesMyocardial inflammationClinical evidenceHeart syndromeExcess mortalityClinical studiesNovel biomarkersT1DTherapeutic implicationsTherapeutic targetType 2Type 1Same diseaseT2D.DiseaseDiagnostic assaysT1D.Depression among patients with diabetes mellitus in North India evaluated using patient health questionnaire-9
Thour A, Das S, Sehrawat T, Gupta Y. Depression among patients with diabetes mellitus in North India evaluated using patient health questionnaire-9. Indian Journal Of Endocrinology And Metabolism 2015, 19: 252-255. PMID: 25729687, PMCID: PMC4319265, DOI: 10.4103/2230-8210.149318.Peer-Reviewed Original ResearchPrevalence of depressionMicrovascular complicationsDiabetes mellitusType 2 diabetes mellitusPatient Health Questionnaire-9Duration of diabetesTertiary care hospitalAssociation of depressionType 2 diabetesYears of ageNorth IndiaCare hospitalEndocrinology clinicPoor outcomeQuestionnaire-9Plasma glucoseSevere depressionModerate depressionHigh prevalenceMild depressionPatientsDiabetesRural subjectsSociodemographic profilePrevalence
2011
Utility of Hemoglobin A1c for Diagnosing Prediabetes and Diabetes in Obese Children and Adolescents
Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, Guandalini C, Savoye M, Rose P, Caprio S. Utility of Hemoglobin A1c for Diagnosing Prediabetes and Diabetes in Obese Children and Adolescents. Diabetes Care 2011, 34: 1306-1311. PMID: 21515842, PMCID: PMC3114343, DOI: 10.2337/dc10-1984.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testType 2 diabetesObese childrenDiabetes categoriesUse of A1CUtility of hemoglobinPrevalence of prediabetesNormal glucose toleranceAmerican Diabetes AssociationGlucose tolerance testDiagnosis of diabetesDiagnostic toolPoor diagnostic toolA1C categoryBaseline A1CMicrovascular complicationsGlucose toleranceDiabetes AssociationPediatric populationTolerance testMultiethnic cohortA1c measurementA1CDiabetesPrediabetes
2010
The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T. The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care 2010, 33: 1269-1274. PMID: 20332354, PMCID: PMC2875436, DOI: 10.2337/dc09-2042.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioContinuous glucose monitoringType 1 diabetic patientsImproved glucose controlCost-effectiveness analysisGlucose controlDiabetic patientsGlucose monitoringBenefits of CGMType 1 diabetes complicationsTest strip useType 1 diabetesCost-effectiveness ratioStandard glucose monitoringMicrovascular complicationsDiabetes complicationsTrial populationSocietal cost-effectiveness analysisGlycemic benefitsLong-term effectsMAIN OUTCOMELife benefitsQALY thresholdStrip useTrial data
2006
The Association of Psychological Factors, Physical Activity, Neuropathy, and Quality of Life in Type 2 Diabetes
Chyun DA, Melkus GD, Katten DM, Price WJ, Davey JA, Grey N, Heller G, Wackers FJ. The Association of Psychological Factors, Physical Activity, Neuropathy, and Quality of Life in Type 2 Diabetes. Biological Research For Nursing 2006, 7: 279-288. PMID: 16581898, DOI: 10.1177/1099800405285748.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnxietyAttitude to HealthConnecticutCoronary DiseaseCross-Sectional StudiesDepressionDiabetes Mellitus, Type 2Diabetic NeuropathiesFemaleHostilityHumansLinear ModelsMaleMiddle AgedMotor ActivityMultivariate AnalysisQuality of LifeRisk FactorsSocioeconomic FactorsSurveys and QuestionnairesVirginiaConceptsQuality of lifeBody mass indexDepressive symptomsMass indexPhysical inactivityMedical Outcomes Study Short Form-36Diabetes-related microvascular complicationsHigher Body Mass IndexPoor QOLAsymptomatic Diabetics (DIAD) studyCardiac risk factorsDiabetes-related factorsShort Form-36Type 2 diabetesPsychological factorsDetection of ischemiaMicrovascular complicationsForm-36Diabetes QualityFemale sexRisk factorsAncillary studiesDiabetic studyPhysical activityType 2
2005
Insulin Pump Treatment of Childhood Type 1 Diabetes
Weinzimer SA, Sikes KA, Steffen AT, Tamborlane WV. Insulin Pump Treatment of Childhood Type 1 Diabetes. Pediatric Clinics Of North America 2005, 52: 1677-1688. PMID: 16301088, DOI: 10.1016/j.pcl.2005.07.004.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionQuality of lifeLong-term microvascular complicationsEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusInsulin pump treatmentChildhood Type 1Risk of hypoglycemiaBlood sugar levelsSubcutaneous insulin infusionNew insulin analoguesTreatment of childrenMicrovascular complicationsDiabetes mellitusPump treatmentSevere hypoglycemiaHemoglobin levelsTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analoguesType 1Weight gain
2004
Rediscovery of insulin pump treatment of childhood type 1 diabetes.
Weinzimer SA, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica 2004, 95: 85-92. PMID: 15272243.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionInsulin pump therapyQuality of lifeSevere hypoglycemiaPump therapyLong-term microvascular complicationsEfficacy of CSIIType 1 diabetes mellitusWeight gainChildhood type 1 diabetesExcessive weight gainBasal infusion rateSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenContinuous glucose monitoringMicrovascular complicationsDiabetes mellitusPediatric patientsHemoglobin levelsNocturnal hypoglycemiaTreatment optionsNormal glycemiaInsulin infusion
1982
Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy.
Tamborlane WV, Puklin JE, Bergman M, Verdonk C, Rudolf MC, Felig P, Genel M, Sherwin R. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982, 5 Suppl 1: 58-64. PMID: 7188047.Peer-Reviewed Original ResearchConceptsPump treatmentProliferative retinopathyMetabolic controlInsulin pumpType I diabetic patientsFirst monthInsulin pump treatmentRetinal fluorescein leakageDiabetic microvascular complicationsTotal daily doseNormal glucose metabolismLong-term improvementBackground retinopathyMicrovascular complicationsCreatinine clearanceDiabetic nephropathyRenal functionSerum creatinineDaily doseDiabetic patientsDiabetic microangiopathyHemoglobin levelsPump therapyPlasma glucoseClinical endpoints
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply